arrow
M

Monica Valente

University of Siena
H指数:19
被引数:1,537

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neurological adverse events of ICI therapy: a ten-year comprehensive management from a multidisciplinary team

ICI疗法相关的神经不良事件:一个多学科团队十年的综合管理

2025-08-090
OAAI
Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma

II期PANDORA试验的设计与原理:晚期默克尔细胞癌的一线化疗免疫疗法

2025-06-120
OA
Nivolumab plus ipilimumab and ASTX727 or nivolumab plus ipilimumab in PD-1 resistant metastatic melanoma: Primary analysis of the randomized phase II NIBIT-ML1 study

纳武利尤单抗联合伊匹木单抗和ASTX727或纳武利尤单抗联合伊匹木单抗治疗PD-1耐药性转移性黑色素瘤:随机II期NIBIT-ML1研究的初步分析

2024-09-010
PRE
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial (vol 199, 113531, 2024)
2024-05-010
PRE
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
2024-03-017
OA
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database
2024-01-043
OAAI
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma
2022-04-0523
OAAI
Skip pattern approach toward the early access of innovative anticancer drugs
2021-08-012
OAAI
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial
2019-12-1355
PREAI